ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
67 announcements
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹702.7 Cr (+16.6% YoY) and net profit of ₹132.2 Cr (-15.0% YoY) for Q4 FY26.
Dr. Lal PathLabs Ltd. reported its FY26 audited results and recommended a final dividend of INR 4/- per share. The company also announced the 100% acquisition of Shahbazkers Diagnostic Centre for up to INR 20 Crore and the incorporation of a new subsidiary in Dubai to expand its diagnostic services footprint.
Dr. Lal Path Labs Ltd has scheduled a board meeting on April 30, 2026, to approve audited financial results and recommend a final dividend for FY 2025-26. The trading window remains closed until May 2, 2026.
Dr. Lal Path Labs Ltd. has scheduled a board meeting for April 30, 2026, to approve audited financial results and recommend a final dividend for FY 2025-26. The trading window remains closed until May 2, 2026.
Dr. Lal PathLabs Ltd informed exchanges that its Board meeting on April 30, 2026, will now also consider and recommend a Final Dividend for FY 2025-26. This is in addition to approving the audited financial results for the quarter and year ended March 31, 2026.
Dr. Lal Pathlabs Ltd reported net profit of ₹91.4 Cr (-6.8% YoY) for Q3 FY26.
Dr. Lal Pathlabs Ltd reported net profit of ₹91.4 Cr (-6.8% YoY) for Q3 FY26.